Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 April 2019 | Story Mamosa Makaya

Since 2016, the University of the Free State Center for Universal Access and Disability Support (CUADS) has received a grant from First National Bank worth R2 498 000, which supports tertiary bursaries for students with disabilities. Bursary holders are funded through CUADS, as the administrator of the bursaries.
  
These are students enrolled for various academic programmes who require academic assistance and/or assistive devices such as electronic handheld magnifiers, laptops, and hearing aids. The FNB grant also covers tuition, accommodation, study material and books, and meals.  The success of the grant is already evident, with one of the recipients having graduated with a Bachelor of Arts degree in December 2018. A second student was capped at the April 2019 graduations with a BSc Honours in Quantity Surveying.
 
Supporting the principles of the ITP

The UFS received the grant from FNB in instalments, starting in the 2016 academic year to date, supporting the needs of 40 disabled students. This grant and the work of CUADS speaks to and supports the principles of the Integrated Transformation Plan (ITP), namely inclusivity, transformation, and diversity. The vision of the Universal Access work stream is to enable the UFS to create an environment where students with disabilities can experience all aspects of student life equal to their non-disabled peers. The ITP provides for the recognition of the rights of people with disabilities as an important lesson in social justice and an opportunity to reinforce university values.

The successful administration of the grant to benefit past and present students is a ‘feather in the cap’ of CUADS, and is a shining example of the impact of public private investment and the endless possibilities that open up when there is a commitment to developing future leaders in academic spaces, allowing them to thrive by creating a learning environment that is welcoming and empowering. 



News Archive

Researchers receive study grant for research into Congo Fever
2015-03-10

UFS researchers will be contributing significantly to the search for a vaccine against the deadly tick-borne disease known as Congo Fever.

Prof Felicity Burt from the Department of Medical Microbiology and Virology was recently awarded a research grant by the National Health Laboratory Service (NHLS) to study candidate vaccines for Crimean-Congo heamorrhagic fever (CCHF) virus and other arboviruses.

Arboviruses are viruses transmitted by mosquitoes, ticks, or other arthropods.

Prof Burt is an internationally-recognised expert on the Crimean-Congo haemorrhagic fever (CCHF). The Crimean-Congo haemorrhagic fever (CCHF) virus is a tick-borne virus that is associated with severe haemorrhagic disease in South Africa and other parts of Africa, Asia, and eastern Europe. Her interests focus on medically significant viruses that are transmitted by ticks and mosquitoes. Her research group is involved in determining the immune responses that are induced by different viral proteins.

Crimean-Congo haemorrhagic fever (CCHF) virus, a tick- borne virus found in Africa, Asia, the Balkans, and eastern Europe, causes severe viral haemorrhagic fever outbreaks.

Although a number of tick species are capable of becoming infected with CCHF virus, ticks of the genus Hyalomma, commonly referred to in SA as the “bont-legged ticks”, are the principal vector. The ticks have distinctive brown and white bands on their legs.

In February 1981, the first case of CCHF was recognised in South Africa (SA). To date, there have been nearly 200 cases of CCHF infection in SA with a 20% fatality rate. The majority of cases occurring in SA were in patients from the Northern Cape and Free State provinces.

“The funding that has been awarded will be used to profile immune responses against CCHF viral proteins, and investigate mechanisms and strategies to enhance these immune responses. We hope that the study will contribute knowledge towards the development of a vaccine against this medically significant virus.”

For more information or enquiries contact news@ufs.ac.za.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept